Accessibility Menu
Black Bird Biotech logo

Black Bird Biotech(OTC) BBBT

Market Cap$3.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
Black Bird Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-14
Black Bird Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-02
1 month+0%USD 0.002026-06-10
3 month+0%USD 0.002026-04-06
Year to date+0%USD 0.002025-12-29
1 year+0%USD 0.002025-07-14
3 year-99.5%USD 0.002023-07-14
5 year-100%USD 0.032021-07-15
Since inception-100%USD 0.162020-01-03

Black Bird Biotech Financials at a Glance

Market Cap

$3.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.32K

Net Income (TTM)

-$1.02M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-6.04 (Low)

Price

$0.00

Volume

50,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 22, 2024

BBBT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Black Bird Biotech

Black Bird Biotech, Inc. operates within the biotechnology sector, focusing on innovative products that cater to both agricultural and consumer markets. The company is known for its unique plant-derived biopesticide, MiteXstream, and a diverse range of consumer goods under the Grizzly Creek Naturals brand.

Products and Services
  • MiteXstream, a biopesticide designed to eliminate spider mites
  • Grizzly Creek Naturals, offering CBD oils, gummies, and pet treats
  • CBD-infused personal care items and hand sanitizers
Growth Outlook
  • Participation in the Montana Hemp pilot program enhances market opportunities
  • Expansion of product lines aims to capture a growing consumer base
  • Focus on sustainable agricultural solutions aligns with industry trends
Financial Highlights
  • Q3 2023 revenue of 3,937, a decrease from Q2's 12,922
  • Net income for Q3 2023 was -131,227, reflecting ongoing operational challenges
  • Current liabilities significantly exceed current assets, indicating liquidity concerns
Black Bird Biotech, Inc. is positioned in a niche market with its biopesticide and CBD product offerings. The company’s flagship product, MiteXstream, addresses a critical need in pest management, while the Grizzly Creek Naturals brand caters to the growing demand for CBD-infused products. Despite recent financial challenges, including a notable decline in revenue and net income, the company is actively pursuing growth opportunities through participation in hemp cultivation and product diversification. The financial landscape indicates a need for strategic management of liabilities and operational efficiency to enhance overall performance. Investors may find interest in the company's innovative approach and potential for future growth within the biotechnology sector.
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

Nelson W. Grist

Website

blackbirdbiotech.com

Headquarters

Argyle, TX 75028, US

BBBT Financials

Key Financial Metrics (TTM)

Gross Margin

-67.71%

Operating Margin

-1560.42%

Net Income Margin

-2009.09%

Return on Equity

-16554.55%

Return on Capital

-6571.45%

Return on Assets

-759.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.73B

Volume

50.00K

Avg. Volume

22.70K

Financials (TTM)

Gross Profit

$13.31K

Operating Income

-$314.55K

EBITDA

-$258.33K

Operating Cash Flow

-$233.06K

Capital Expenditure

$0.00

Free Cash Flow

-$233.06K

Cash & ST Invst.

$5.73K

Total Debt

$748.11K

Black Bird Biotech Performance Analysis

Black Bird Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 104,458N/A
20222022-12-31USD 82,563-21.0%
Black Bird Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-53.1%
Q12023-03-31-38.9%
Q22023-06-3075.0%
Q32023-09-30-69.5%
Black Bird Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.01N/A
20222022-12-31USD -0.01-46.2%
Black Bird Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31-25.0%
Q22023-06-3070.0%
Q32023-09-3066.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$3.94K

-84.7%

Gross Profit

$1.42K

-89.4%

Gross Margin

36.02%

N/A

Market Cap

$3.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$925.00

N/A

Employees

4

N/A

Net Income

-$131.23K

+51.6%

EBITDA

$41.71K

+126.7%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$5.73K

-91.3%

Total Debt

$748.11K

+14.2%

Accounts Receivable

$1.55K

-60.3%

Inventory

$75.46K

-16.3%

Long Term Debt

$2.88K

N/A

Short Term Debt

$745.23K

+13.8%

Return on Assets

-7.59%

N/A

Return on Invested Capital

1.98%

N/A

Free Cash Flow

-$4.90K

+96.1%

Operating Cash Flow

-$4.90K

+96.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADVTAdvantis Corp.
$0.00+0.00%
EAPHParallel Industries Inc.
$0.00+0.00%
PBLAPanbela Therapeutics, Inc.
$0.01+0.00%
NVOSNovo Integrated Sciences, Inc.
$0.00+5.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About BBBT

What is the current price of Black Bird Biotech?

Black Bird Biotech is trading at $0.00 per share.

What is the 52-week range for Black Bird Biotech?

Over the past 52 weeks, Black Bird Biotech has traded between $0.00 and $0.00.

How much debt does Black Bird Biotech have?

As of the most recent reporting period, Black Bird Biotech reported total debt of $669.78K.

How much cash does Black Bird Biotech have on hand?

Black Bird Biotech reported $44.45K in cash and cash equivalents in its most recent financial results.

What is Black Bird Biotech’s dividend yield?

Black Bird Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services